PART II: WALTER HUBERT LECTURE CHEMOTHERAPY OF UPPER GASTROINTESTINAL CARCINOMA C. G. MOERTEL, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, U.S.A.
In the Western world, carcinoma of the pancreas has waxed as gastric cancer has waned, but both remain as major causes of cancer mortality. Carcinoma of the stomach dominates the cancer incidence of Asia and the Soviet Union. Cancers of the liver and oesophagus ravage the continent of Africa in almost epidemic proportions. In spite of the great human need which this problem presents, there are few areas where the inadequacies of modern medicine are so apparent as in the management of upper gastrointestinal cancer. With all the sophistication of our diagnostic approaches, and with the ingenuity and heroism of the surgical attack, end-result statistics show that over 95% of patients found to have cancer of the oesophagus, liver, biliary tract, or pancreas will die of their disease, as will almost 90% of patients with gastric cancer. These grim statistics have changed little if at all over the past 30 years. Until methods can be evolved for either prevention or for practical detection of upper gastrointestinal carcinoma in the asymptomatic state, we must deal with the problem as the patient presents it to us, and clearly this is not at a stage amenable to surgical cure. There would not seem to be a realistic hope that advances in surgical technique per se can subsequently change these statistics. The results of surgery essentially plateaued a quarter of a century ago. Any progress, it would seem, must be derived from nonsurgical approaches. Among these, radiation therapy is hampered by its regional restriction and by lack of specificity. Immunotherapy has, as yet, no track record and may be largely an illusion. In spite of all its limitations, the most tangible hope in the foreseeable future would seem to rest with chemotherapy.
Chemotherapy of gastrointestinal carcinoma had its beginnings with the development in clinical application of 5-fluorouracil (5-FU) some 18 years ago. Early reports of the therapeutic effectiveness of this and other agents presented the reader with such a confusing labyrinth of claims and counterclaims that an aura of witchcraft hovered over those engaged in this field. New drugs or methods were extravagantly praised by one investigating group only to be damned by another. Objective response rates with 5-FU therapy of large bowel cancer, for example, were reported over the astounding range of 8 to 85%, even though all investigators were treating the same neoplasm with the same drug by the same dosage schedule (Moertel and Reitemeier, 1969) . After these initial reports, numerous new wrinkles for administering 5-FU, or its blood-brother 5-fluoro-2'-deoxyuridine (FUdR), were devised and would predictably be advocated by the devisers as having improved therapeutic effectiveness. Such claims, however, could be regarded as little more than testimonials, since they were not validated by concurrent control groups. The reader was left-with the impossible task of judging whether the reporting investigator at that point in time was an 8 percenter or an 85 percenter. Over the past decade, the mediaeval methodology of our earlier chemotherapy trials in gastrointestinal cancer has slowly, and sometimes painfully, given way to more meaningful and reproducible scientific approaches. Although some still cling to the delusion that they can devise historical controls for retrospective comparisons, it has now become the more accepted practice for comparative clinical trials to be prospective and randomized in design. Considerable progress has also been made in defining, standardizing, and communicating the results of clinical trials. A number of factors have been elucidated which contributed to the striking variations in response rate reported in the earlier literature. For almost all areas of therapeutics it is evident that far-advanced disease, producing severe physiologic alteration, will be far less likely to respond to either surgical or medical treatment than an earlier and less devastating stage of the disease. This difference, it would seem, should be seen in even bolder relief for patients subjected to stressful cytotoxic drugs with a narrow therapeutic ratio. In Table I the results of chemotherapy of gastrointestinal cancer are related to the degree of disability of the patient at the time treatment In the main, we must deal with partial regressions of vaguely defined lumps and livers. A great deal of faith must be placed in the objectivity of the investigator, and even then it must be realized that he is fully subject to the human frailty of committing error. We have recently completed a study of reproducibility of measurements of lumps (Moertel and Hanley, in press) . In this study the investigators measured simulated tumour masses in pairs of the same size but under circumstances where the investigators did not know they were the same. We observed striking differences in measured sizes, to Treatment of gastrointestinal cancer with 5-fluorouracil 5-fluorouracil (5-FU) was the first chemotherapeutic agent to prove capable of inducing tumour regressions of gastrointestinal adenocarcinoma in the hands of all investigators reporting its use. Although the true therapeutic value of this agent may be questioned, it has nevertheless served as a stimulus and catalyst for clinical research in the treatment of this most common group of neoplasms.
In an attempt to improve the therapeutic ratio of 5-FU, this agent has been delivered through every natural or artificial orifice into almost every available human lumen by every conceivable dosage schedule. Predictably, each new approach has been lauded by the initiator as more effective, less toxic, and eminently suitable for office practice. Equally predictably, none of these claims have stood the test of a controlled clinical trial. Noteworthy conclusions of these controlled trials have been the following: (1) the nucleoside of 5-FU, 5 fluoro-2'-deoxyuridine (FUdR), does not have any significant clinical advantage over 5-FU (Reitemeyer, Moertel and Hahn, 1965) ; (2) slow infusion of these fluorinated pyrimidines adds expense and nuisance to the treatment procedure but not improved therapeutic efficacy (Reitemeyer and Moertel, 1962; Moertel, Reitemeyer and Hahn, 1967; Moertel et al., 1972) ; (3) the oral route of administration of 5-FU is associated with erratic drug absorption and significantly inferior therapeutic effect, regardless of administration schedule (Hahn et al., 1975; Bateman et al., 1975; Ansfield, 1975) and (4) weekly administration of 5-FU is significantly inferior to the loading course method (Ansfield, 1975) . Table IV would seem to put the fluorinated pyrimidine question into proper prospective. Here we have related the objective response rates to 5-FU or FUdR, regardless Single agent therapy To this date, our primary task in chemotherapy of pancreatic and gastric carcinoma has been a search for single agents that will show some evidence of significant activity when used alone and, hopefully, will form the basis for a later evolution of combination drug therapy regimens. In this quest, we have followed largely an empirical road. Table V shows our single-agent experiences with advanced pancreatic carcinoma. These have been singularly discouraging. brighter picture in gastric carcinoma, however, it would seem quite clear that single-drug therapy has not provided substantive benefit in any type of gastrointestinal cancer. Much of our more recent efforts have, therefore, been directed towards combination drug therapy. As a rule of thumb, we feel that for drugs to be effective in combination, they must show some evidence of activity when used alone. Combining ineffective drugs has inevitably led to ineffective combinations. Also, we have felt that one must be able to use the constituent drugs together with a less than proportionate summation of their toxic effects. Our first study in this regard was an evaluation of combinations involving 5-FU, Mitomycin C, and BCNU. In pilot studies, we found that when Mitomycin C and BCNU were used in double combination, you could use only one-half of a full dose of each. Mitomycin C and 5-FU looked a bit better, permitting two-thirds of a full dose of each. 5-FU and BCNU look particularly attractive since 75% of the full dose could be combined with no more toxicity than using either of the drugs alone. With this background, we then initiated a controlled evaluation, randomizing 215 patients with gastrointestinal cancer to treatment with each of the single drugs, with each of the three possible double drug combinations, and with the triple drug combination (Reitemeier, Moertel and Hahn, 1970) . Regrettably, none of the combinations performed any better than 5-FU alone and most of them were worse. We were particularly disappointed with combined 5-FU and BCNU which had demonstrated only a minor and insignificant increase in duration of response. In this study, as was common practice in that era, we put all the specific types of gastrointestinal cancers into the same pot in the 3B.A.C.R. 17TH ANNUAI GENERAL MEETING belief that they would all respond the same. In recent years, it has become evident that this is an erroneous assumption. All gastrointestinal cancers are not alike. When we looked at our responses of specific cancers to combined 5-FU and BCNU, we found that the response rate for colorectal cancer was abominable and this negative observation has subsequently been confirmed by Lokich and associates. On the other hand, the response rate in a very small group of gastric and pancreatic carcinomas looked remarkably good. With this encouragement we expanded our controlled study to a much larger group of 167 gastric and pancreatic cancer patients randomized to 5-FU alone, BCNU alone, and the 5-FU/BCNU combination (Table VII) (Kovach et al., 1974 With this glimmer of success, we then turned our attention to the newer nitrosourea analogues, particularly to methyl CCNU. This drug has the advantage of an oral route of administration whereas BCNU has to be given i.v. Also, methyl CCNU seems to have some therapeutic advantage in animal models. In the Eastern Cooperative Oncology Group, therefore, we initiated a study in gastric cancer comparing methyl CCNU alone with the combination of 5-FU and methyl CCNU (Moertal et al., in press) . In this study we threw in the wrinkle of cyclophosphamide induction, and that was a total failure (Table VIII) . The combination of superior to that achieved with methyl CCNU alone. In addition, survival of patients treated with the combination was also significantly superior to that for patients treated with the single drug. Further confirmation of the effectiveness of this combination has come from studies by the Southwest Oncology Group (Baker et al., 1975) (Table IX) . This study involved a spectrum of upper gastrointestinal carcinomas and compared the Chemotherapy of oesophageal carcinoma Squamous cell carcinoma is not an uncommon malignant disease and surgical results have been characterized by an operative mortality rate that exceeds the cure rate. It is surprising that chemotherapy experience with this disease has been so meagre. Bleomycin has perhaps had the largest overall clinical application. The reported response rates with this drug, however, are far from impressive. Among 14 consecutive patients we treated with bleomycin as a single agent, we did not observe any evidence of therapeutic activity. Our only other trial has been with the nitrosourea, CCNU. Here we observed 3 responses among 19 patients treated and these persisted for periods of only 2, 3 and 9 months. Certainly this is nothing approaching a therapeutic accomplishment. Our present effort in oesophageal carcinoma must be in Phase II evaluations of single drugs, with the hope that we can unearth at least a few agents with some degree of activity that can form the constituents of rational drug combinations.
Chemotherapy of hepatocellular carcinoma (Table XI) We have had occasional brief responses with systemic 5-FU, and others have noticed (Davis, Ramirez and Ansfield, 1974) , however, have shown that the expensive and cumbersome intra-arterial approaches really contribute nothing significant to patient survival. Of special interest to us has been the quite impressive response rate we have achieved with combined 5-FU and BCNU therapy.
Thirty-seven per cent of our patients have shown tumour regression and 3 of these were of very long duration. In a recently completed joint African and American study of hepatoma therapy (Falkson, Moertel and Lavin, 1976) , adriamycin as well as the combinations of 5-FU plus each of the 2 nitrosoureas, methyl CCNU and streptozotocin, all produced a significant improvement in survival of hepatoma patients when compared to treatment with 5-FU alone. We are now most interested in pursuing the 3 drug combinations of 5-FU, methyl CCNU and adriamycin.
Chemotherapy of the carcinoid tumour and the malignant carcinoid syndrome
The malignant carcinoid syndrome provides a dramatic event in oncologic practice. We must, however, restrain our zeal to expose these patients to the hazards of cytotoxic drugs at an early stage of the disease. This tumour is exceedingly indolent and patients can frequently have several years of productive life before the disease causes them any real disability. Although the carcinoid syndrome may be fascinating to the physician, its early stages seldom cause the patient more problems than an occasional blush and mild diarrhoea which can be controlled with standard symptomatic measures. All the patients listed Table XII,   TABLE XII ever, has written a new chapter in the treatment of these neoplasms. Among a collected series of 56 patients with hormonally active islet-cell carcinomas reported by Broder and Carter (1973) , functional improvement was observed in 64% and objective tumour regression was seen in 37%.
We have observed 3 objective responses among 6 patients, one of which was most dramatic, in a patient near death with a fulminating pancreatic cholera syndrome, showing a high rate response to the 5-FU/ streptozotocin combination. Some of these responses have also been of a very striking nature and of very long duration. This combination is currently being compared in a controlled study with streptozotocin used alone.
CONCLUSIONS
Until the very recent past, chemotherapy of upper gastrointestinal cancer was largely an academic endeavour with no evidence of substantive contribution to the overall population of patients treated, whether measured in terms of symptomatic palliation or improved survival time. Now, however, it is possible to recognize a few definite steps of progress. Refinements of methodology have allowed data to be communicated in a meaningful way. In comparative trials, the randomized prospective design now permits believable differences to become apparent without the cloud of subjectivity and artefacts that obscures the testimonial-type reports or the study based only on historical controls. Although 5-FU probably remains the most active single drug in upper gastrointestinal cancer, definite antineoplastic effect has been demonstrated for a number of other agents. It does, however, seem obvious that no single drug therapy has been of significant value for the upper gastrointestinal cancer patient, whatever the stage of the disease at which it is administered. Following the path that has led to success in leukaemia, lymphoma and breast cancer, increasing emphasis is now placed on combination chemotherapy regimens for upper gastro-intestinal cancer. Combined 5-FU and nitrosourea therapy has increased response rate for carcinomas of the stomach, pancreas, and liver to the 30 to 40% range. In gastric carcinoma and in hepatoma this has also been associated with improved patient survival. Combined 5-FU and streptozotocin has produced even higher response rates in the carcinoid tumour and islet-cell carcinoma.
Even though these results may seem exciting, they are certainly far from our ultimate objectives. Responses in advanced disease are still transient and all the patients still die of their disease. None of our approaches for advanced and metastatic upper gastrointestinal cancer are of sufficient value to justify offering as standard or routine treatment. We must continue to regard all patients at this stage of their disease as subjects for clinical research.
It is obvious that the only hope for increasing cure rates for upper gastrointestinal cancer in the foreseeable future lies in the application of chemotherapy, or perhaps immunotherapy, to the patient who has been brought to the point of minimal tumour burden by surgical resection. Surgical adjuvant chemotherapy attempts in the past have been notable only for their failures. The chemotherapy applied under these circumstances, however, has had very little evidence of therapeutic activity, e.g. thiotepa, 5-FU, FUdR and Mitomycin C. With the significantly greater activity now demonstrated by our combination regimens, it would seem appropriate that new efforts at surgical adjuvant therapy be undertaken.
In treating the patient with upper gastrointestinal cancer, it is evident that neither surgeon, radiotherapist, nor oncologist have accomplished anything of real value by working alone or in sequence, nor is there any realistic hope that such solo performances will produce any substantive future accomplishment. If, however, we can offer our patients the best of all concerned disciplines, working together in carefully designed protocols, then I feel we can confidently anticipate significant improvements in the results of treatment for tomorrow's upper gastrointestinal cancer patient.
